The cohort predominantly includes patients with NYHA class III symptoms, with elevated baseline BNP or NTproBNP levels, as is comparable to GUIDE-HF, and suggests advanced disease and a high event rate (4, 13). The gene discussed is NPPB; the disease is hydrops fetalis.